Skip to main content
. 2022 Jul 15;40(36):4261–4275. doi: 10.1200/JCO.21.02707

FIG 5.

FIG 5.

PTCL-NOS subclassification. (A) Violin and dot plots of PTCL-GATA3 classification scores in PTCL-NOS cases profiled in the training and validation cohorts on the nCounter. (B) Mutation status of the PTCL-NOS cohort with available sequencing data. (C) Heatmaps of expression of CD4, CD8, CD20, and cytotoxic genes in the training (upper) and validation (lower) cases. In CD4-positive lymphomas, the CD8 expression is likely contributed from the tumor microenvironment. (D) Scatterplot of the average expression of the cytotoxic genes versus CD20 in cases that classified as PTCL-TBX21 by NanoString. (E) H&E and IHC stains for one representative PTCL-GATA3 case showing GATA3 (left) and one PTCL-TBX21 case showing TBX21 and CD8 expression (right). (F) Kaplan-Meier curve of OS for PTCL-NOS cases with available outcome data in the combined training and validation cohorts classified as PTCL-GATA3 or PTCL-TBX21 NanoString. AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ATLL, adult T-cell lymphoma/leukemia; ENKTCL, extranodal natural killer/T-cell lymphoma; IHC, immunohistochemistry; NOS, not otherwise specified; OS, overall survival; PTCL, peripheral T-cell lymphoma; WT, wild-type.